Short Interest in Propanc Biopharma, Inc. (OTCMKTS:PPCB) Grows By 310,000.0%

Propanc Biopharma, Inc. (OTCMKTS:PPCBGet Rating) saw a large growth in short interest during the month of May. As of May 15th, there was short interest totalling 310,100 shares, a growth of 310,000.0% from the April 30th total of 100 shares. Based on an average trading volume of 149,561,400 shares, the short-interest ratio is presently 0.0 days.

Propanc Biopharma Stock Performance

Propanc Biopharma stock opened at $0.08 on Friday. Propanc Biopharma has a 1 year low of $0.00 and a 1 year high of $0.20. The business has a 50-day moving average of $2.57 and a 200-day moving average of $1.28.

About Propanc Biopharma

(Get Rating)

Propanc Biopharma, Inc is a development-stage healthcare company, which engages in the research and development of cancer treatments. The firm focuses on the treatment of pancreatic, ovarian, and colorectal cancer. It offers its product pipeline, including PRP and POP1. The company was founded by James Nathanielsz and Julian Kenyon on October 15, 2007 and is headquartered in Camberwell, Australia.

See Also

Receive News & Ratings for Propanc Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Propanc Biopharma and related companies with's FREE daily email newsletter.